These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 32499597

  • 21. Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study.
    Papenburg J, Defoy I, Massé E, Caouette G, Lebel MH.
    J Pediatric Infect Dis Soc; 2021 Apr 03; 10(3):237-244. PubMed ID: 32530035
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.
    Ambrose CS, Chen X, Kumar VR.
    Hum Vaccin Immunother; 2014 Apr 03; 10(10):2785-8. PubMed ID: 25483483
    [Abstract] [Full Text] [Related]

  • 25. Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons.
    Anderson EJ, Carbonell-Estrany X, Blanken M, Lanari M, Sheridan-Pereira M, Rodgers-Gray B, Fullarton J, Rouffiac E, Vo P, Notario G, Campbell F, Paes B.
    Pediatr Infect Dis J; 2017 Feb 03; 36(2):160-167. PubMed ID: 27755464
    [Abstract] [Full Text] [Related]

  • 26. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
    Priante E, Tavella E, Girardi E, Militello MA, Mardegan V, Maule MM, Dall'Agnola A, Baraldi E, Manzoni P.
    Am J Perinatol; 2019 Jul 03; 36(S 02):S77-S82. PubMed ID: 31238365
    [Abstract] [Full Text] [Related]

  • 27. Respiratory syncytial virus risk factors in late preterm infants.
    Lanari M, Silvestri M, Rossi GA.
    J Matern Fetal Neonatal Med; 2009 Jul 03; 22 Suppl 3():102-7. PubMed ID: 19925369
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Recent Trends in RSV Immunoprophylaxis: Clinical Implications for the Infant.
    Acero-Bedoya S, Wozniak PS, Sánchez PJ, Ramilo O, Mejias A.
    Am J Perinatol; 2019 Jul 03; 36(S 02):S63-S67. PubMed ID: 31238362
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
    Forbes ML, Kumar VR, Yogev R, Wu X, Robbie GJ, Ambrose CS.
    Hum Vaccin Immunother; 2014 Jul 03; 10(10):2789-94. PubMed ID: 25483663
    [Abstract] [Full Text] [Related]

  • 32. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
    Kim D, Saleem M, Paes B, Mitchell I, Lanctôt KL.
    Clin Infect Dis; 2019 Aug 30; 69(6):980-986. PubMed ID: 30517603
    [Abstract] [Full Text] [Related]

  • 33. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
    Manzoni P, Paes B, Lanctôt KL, Dall'Agnola A, Mitchell I, Calabrese S, Maule M, Girardi E, Harimoto T, Li A.
    Pediatr Infect Dis J; 2017 Jan 30; 36(1):2-8. PubMed ID: 27649365
    [Abstract] [Full Text] [Related]

  • 34. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).
    Wang DY, Li A, Paes B, Mitchell I, Lanctôt KL, CARESS Investigators.
    Eur J Pediatr; 2017 Mar 30; 176(3):413-422. PubMed ID: 28105526
    [Abstract] [Full Text] [Related]

  • 35. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD.
    J Manag Care Pharm; 2010 Mar 30; 16(1):15-22. PubMed ID: 20044843
    [Abstract] [Full Text] [Related]

  • 36. Modeling the Potential Impact of the 2014 American Academy of Pediatrics Respiratory Syncytial Virus Prophylaxis Guidance on Preterm Infant RSV Outcomes.
    McLaurin KK, Chatterjee A, Makari D.
    Infect Dis Ther; 2015 Oct 26; 4(4):503-11. PubMed ID: 26499122
    [Abstract] [Full Text] [Related]

  • 37. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR.
    Pediatr Infect Dis J; 2003 Feb 26; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [Abstract] [Full Text] [Related]

  • 38. Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines.
    Choi Y, Meissner HC, Hampp C, Park H, Winterstein AG.
    Eur J Pediatr; 2022 Feb 26; 181(2):841-845. PubMed ID: 34365543
    [Abstract] [Full Text] [Related]

  • 39. Indications to respiratory syncytial virus immunoprophylaxis in the 29-32 wGA group: is there still room for debating?
    Zuccotti G, Fabiano V.
    Ital J Pediatr; 2017 Feb 02; 43(1):17. PubMed ID: 28257653
    [Abstract] [Full Text] [Related]

  • 40. Prevalence and clinical characteristics of perinatal chronic lung disease by infant gestational age.
    Mavunda K, Jiang X, Ambrose CS.
    J Neonatal Perinatal Med; 2021 Feb 02; 14(1):43-51. PubMed ID: 32474477
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.